Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.
Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.
Sells olverembatinib itself in China, and funds the rest of its pipeline partly from licence fees and milestone payments from larger pharma partners, with a loss-making profile typical of a company paying for late-stage trials. Hospitals in China are the buyers, with insurance reimbursement important for volumes.
In one line: A Chinese AbbVie-style apoptosis/oncology drug developer.
Moat: narrow (IP / patents, first-mover approval). Approved BCR-ABL inhibitor for drug-resistant CML with patent protection.
Headquarters: Suzhou, China · Founded: 2009 · Employees: 767
Size Ascentage Pharma Group International (6855.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 540th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.82 on 18 Nov 2026.
Performance Over six months the shares fell 34.2%, against -11.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 70.3% over the last twelve months (peer median +5.9%); the operating margin is -220.0% (peer median 0.8%).
Valuation It trades at 13.2× enterprise value to sales against a peer median of 7.6× (5th most expensive of 18).
Capital Return on invested capital runs 155.6 points below its cost of capital (8.4% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$717M | HK$623M | HK$1.06B | HK$245M | HK$244M |
| Revenue growth | — | -41% | +333% | +1% | — |
| Gross profit | HK$597M | HK$493M | HK$940M | HK$126M | HK$147M |
| EBITDA | -HK$1.48B | -HK$1.22B | -HK$310M | -HK$900M | -HK$956M |
| Net income | -HK$1.64B | -HK$1.35B | -HK$440M | -HK$1.02B | -HK$1.03B |
| Free cash flow | -HK$1.58B | -HK$1.38B | -HK$213M | -HK$947M | -HK$1.08B |
| Capital expenditure | HK$22.2M | HK$29.9M | HK$26.3M | HK$62.8M | HK$276M |
| Total debt | n/a | HK$2.21B | HK$1.81B | HK$1.98B | HK$2.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ascentage Pharma Group International 6855.HK | $1.18B | -34% | +70% | -220% | 13.2× | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| InnoCare Pharma 9969.HK | $2.01B | -10% | +146% | 35% | 2.8× | -2.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6855.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.8% | -1.6% | 4th lowest of 21 |
| 6-month return | -34.2% | -11.8% | 7th lowest of 20 |
| Distance from 52-week high | -64.1% | -39.3% | 4th lowest of 21 |
| Revenue growth (TTM) | +70.3% | +5.9% | 4th highest of 18 |
| Operating margin | -220.0% | 0.8% | 3rd lowest of 18 |
| EV / Sales | 13.2× | 7.6× | 5th most expensive of 18 |
| ROIC minus cost of capital | -155.6 pp | -7.5 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | 13.3× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 3.5× | 4.2% | +21.7% |